An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic

References

• International agency for research on cancer. globocan 2018. Stomach. 2018 Oct 4. Available from: https://gco.iarc.fr/today/data/fact/sheets/cancers/7-Stomach-fact-sheet.pdf
   Google Scholar
• Bang Y. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46(8):637–648.
   PubMed Web of Science ®Google Scholar
• Maresch J, Schoppmann SF, Thallinger CM, et al. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. Crit Rev Oncol Hematol. 2012;82(3):310–322.
   PubMed Web of Science ®Google Scholar
• Wagner A, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–2909.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Gastric cancer. Vol. 4 of Clinical practice guidelines in oncology. 2019. [Cited 15 Nov 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
   Google Scholar
• Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):19–33.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644–1646.
   PubMed Web of Science ®Google Scholar
• Hudis C. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742): 687–697. 2010.
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–1529.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metast Rev. 2015;34(1):157–164.
   PubMed Web of Science ®Google Scholar
• Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619.
   PubMed Web of Science ®Google Scholar
• Sukawa Y, Yamamoto H, Nosho K, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 2014;89(1):12–17.
   PubMed Web of Science ®Google Scholar
• Stahl P, Seeschaaf C, Lebok P, et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 2015;15(1):1–13.5.
   PubMedGoogle Scholar
• Sanford M. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. Drugs. 2013;73(14):1605–1615.
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–650.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:1–9.
   Google Scholar
• Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer. 2012;3:137.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–2662.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805.
   PubMed Web of Science ®Google Scholar
• de Mello RA, Marques AM, et al. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013;19(37):6165.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384.
   PubMed Web of Science ®Google Scholar
• Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: tyTAN—a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–2049.
   PubMed Web of Science ®Google Scholar
• Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol. 2013;85(3):350–362.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–127.
   PubMed Web of Science ®Google Scholar
• Matsubara J, Yamada Y, Hirashima Y, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 2008;14(10):3022–3029.
   PubMed Web of Science ®Google Scholar
• Xu Z, Guo D, Jiang Z, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody–drug conjugate,[fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 67(3): 173–185. 2019.
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699.
   PubMed Web of Science ®Google Scholar
• Chari R. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev. 1998;31(1–2):89–104.
   PubMed Web of Science ®Google Scholar
• Panowski S, Bhakta S, Raab H, et al. Site-specific antibody drug conjugates for cancer therapy. mabs. 2014;6(1):34–45. Taylor & Francis.
   PubMed Web of Science ®Google Scholar
• Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.
   PubMed Web of Science ®Google Scholar
• Iwata TN, Ishii C, Ishida S, et al. A HER2-targeting antibody–drug conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17(7):1494–1503.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 22(20): 5097–5108. 2016.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–7070.
   PubMed Web of Science ®Google Scholar
• Kadcyla® BLA. Center for drug evaluation and research application number: 125427orig1s000 medical review(s). 2018 Aug 11. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000MedR.pdf
   Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287.
   PubMed Web of Science ®Google Scholar
• Keam S. Trastuzumab deruxtecan: first approval. Drugs. 2020;80(5):501–508.
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Company Ltd, AstraZeneca. Daiichi Sankyo andAstraZeneca announce global development and commercialization collaboration for Daiichi Sankyo’s HER2 targeting antibody drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) [media release]. 2019 Mar 29. Available at: https://www.daiichisankyo.com/media/press_release/detail/index_3199.html
   Google Scholar
• Mishima S, Shitara K. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opin Biol Ther. 2021;21(7):825–830.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Tsurutani J, Kawakami H, et al. [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145(12):3414–3424.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522.
   PubMed Web of Science ®Google Scholar
• Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827–836.
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 382(25): 2419–2430. 2020.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Bang YJ, Iwasa S, et al. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol. 2020;31:S899–S900.
   Web of Science ®Google Scholar
• Kotani D, Shitara K. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021;13:1758835920986518.
   Web of Science ®Google Scholar
• Daiichi Sankyo Company Ltd. Daiichi Sankyo announces clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfzer to evaluate [fam-] trastuzumab deruxtecan (DS-8201) with avelumab and a DNA damage response inhibitor in patients with HER2 expressing and mutated solid tumors [media release]. 2018 Oct 25. Available at: https://www.daiichisankyo.com/media/press_release/detail/index_3229.html
   Google Scholar
• Daiichi Sankyo Company Ltd, Puma Biotechnology Inc. Daiichi Sankyo and Puma Biotechnology announce research collaboration with major cancer center in HER2-mutated cancer [media release]. 2017 Dec 12. Available at: https://www.daiichisankyo.com/media/press_release/detail/index_3292.html
   Google Scholar
• Squibb B-M. Daiichi Sankyo Company Ltd. BristolMyers Squibb and Daiichi Sankyo announce research collaboration to evaluate Opdivo® (nivolumab) and DS-8201 in HER2- expressing breast and bladder cancers [media release]. 2017 Aug 28. Available at: https://news.bms.com/news/details/2017/Bristol-Myers-Squibb-and-Daiichi-Sankyo-Announce-Research-Collaboration-to-Evaluate-Opdivo-nivolumab-and-DS-8201-in-HER2-Expressing-Breast-and-Bladder-Cancers/default.aspx
   Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–826.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Mori H. Different pathophysiology of gastritis between East and West? An Asian perspective. Inflamm Intest Dis. 2016;1(3):123–128.
   PubMedGoogle Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• Linehan AS, Fitzpatrick OM, Morris PG. Profile of trastuzumab deruxtecan in the management of patients with HER2-positive unresectable or metastatic breast cancer: an evidence-based review. Breast Cancer: Target Therapy. 2021;13:151.
   PubMed Web of Science ®Google Scholar
• García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody–drug conjugates. Cancer Res. 2018;78.9(9):2159–2165.
   Web of Science ®Google Scholar
• Rosen DB, Harrington KH, Cordeiro JA, et al. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One. 2013;8.1(1):e53518.
   Web of Science ®Google Scholar
• Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res. 2006;30.7(7):777–783.
   Web of Science ®Google Scholar
• Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, et al. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77.17(17):4639–4651.
   Web of Science ®Google Scholar
• Trudeau KM, Colby AH, Zeng J, et al. Lysosome acidification by photoactivated nanoparticles restores autophagy under lipotoxicity. J Cell Biol. 2016;214.1(1):25–34.
   Web of Science ®Google Scholar